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Summary: This article provides practical recommendations developed from the Interna-
tional Society of Gynecological Pathologists Endometrial Carcinoma Project to address 4
issues that may arise in the diagnosis of uterine corpus low-grade endometrioid carcinoma:
(1) The distinction between atypical hyperplasia and low-grade endometrioid carcinoma. (2)
The distinction between low-grade endometrioid carcinoma and serous carcinoma. (3) The
distinction between corded and hyalinized or spindle cell variants of low-grade endometrioid
carcinoma and carcinosarcoma. (4) The diagnostic criteria for mixed endometrial
carcinomas, a rare entity that should be diagnosed only after exclusion of a spectrum of
tumors including morphologic variants of endometrioid carcinoma, dedifferentiated
endometrial carcinoma, carcinosarcoma, and endometrial carcinomas with ambiguous
morphology. Key Words: Endometrial cancer—Atypical hyperplasia—Serous carcinoma—
Mixed carcinoma.
Approximately 80% of endometrial carcinomas
are of endometrioid type and most of these are
morphologically low grade (International Federation
of Gynecology and Obstetrics [FIGO] grade 1 or 2).
A variety of problems may occur in the diagnosis of
low-grade endometrioid carcinomas; some of these
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are discussed herein and practical recommendations
to aid in diagnosis are provided. These recommenda-
tions were developed by the authors as part of the






(1) The presence of glandular crowding with endome-
trial stromal exclusion and significant cribriform,
confluent glandular, labyrinthine, papillary/villo-
glandular, or nonsquamous solid architecture dis-
tinguishes low-grade endometrioid carcinoma from
atypical hyperplasia. These features may be present
alone or in combination.
(2) The definition of the minimum amount (size of
span, surface area, or number of fragments) of these
patterns needed to diagnose low-grade endometrioid
carcinoma is not resolved and remains a subjective
interpretation by the individual pathologist in an
individual case.
(3) If the morphologic features are suspicious but do not
fully meet the criteria for endometrioid carcinoma,
this concern should be communicated descriptively in
the pathology report rather than being classified as
atypical hyperplasia without further comment.
(4) There are no diagnostically useful biomarkers to
distinguish between atypical hyperplasia and low-
grade endometrioid carcinoma.
Discussion
The standard management of atypical hyperplasia
(synonymous terminology is endometrioid intraepithelial
neoplasia) (Fig. 1) is total hysterectomy whereas additional
surgical staging may be considered for low-grade
endometrioid carcinoma (Fig. 2) (1,2). Thus, setting
aside nonsurgical options for women wishing to preserve
fertility, there is clinical merit in attempting to distinguish
atypical hyperplasia from low-grade endometrioid
carcinoma in preoperative endometrial samples.
Proposed criteria for defining low-grade endome-
trioid carcinoma are largely drawn from studies
designed to identify morphologic features in an
endometrial biopsy or curettage that predict myoin-
vasive endometrioid carcinoma in a subsequent
hysterectomy (3–5). Key predictors include glandular
crowding with endometrial stromal exclusion and
significant cribriform, confluent glandular, labyrinthine,
papillary/villoglandular, or nonsquamous solid archi-
tecture (Fig. 2). The minimal amount of such findings
that qualify for a diagnosis of carcinoma have been
studied only to a limited degree and the conclusions
depend on the desired combination of sensitivity and
specificity for predicting myoinvasive cancer. Proposed
minimum thresholds to define cancer include a size of
2.1mm of any single fragment, an aggregate size of at
least 3mm, whether a single fragment or multiple
smaller fragments (5), or 30% volume of the sample
involved by these features (4). Notably, at least 1 study
reported that the presence of any amount of cribriform
growth regardless of size was predictive of myoinvasive
cancer (5). Presently, there is not enough evidence to
define a specific minimum amount of any of these
growth patterns and so the interpretation is left to the
individual pathologist in each individual case. On
occasion, the features in a biopsy may be at the cusp
between atypical hyperplasia and grade 1 endometrioid
carcinoma without fully meeting criteria to classify
outright as cancer (Figs. 1C, D). At least 1 study
demonstrated that these patients have a higher
incidence of cancer in the subsequent hysterectomy
compared with patients whose biopsy exhibits atypical
hyperplasia without any concerning features for cancer
(6). This suggests that such cases should not be reported
merely as a conventional atypical hyperplasia but that
the strong suspicion for cancer should be discussed in
the pathology report.
The proposed architectural criteria for cancer are
most predictive in samples that contain adequate,
intact tissue and are challenging to apply in samples
where the amount of tissue is limited in size or the
tissue is highly fragmented or disrupted. Diagnostic
subjectivity in assessing these qualitative criteria may
also contribute to discordance between biopsy and
hysterectomy findings and discordance between ob-
servers in classifying biopsy and/or hysterectomy
features (7,8).
There are no immunohistochemical markers that
facilitate the distinction between atypical hyperplasia





(1) The morphologic concordance/discordance be-
tween glandular/papillary architecture and nuclear
atypia distinguishes most low-grade endometrioid
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carcinomas from glandular and papillary patterns
of serous carcinoma. The former typically exhibits
concordant low-grade architecture and low-grade
nuclear atypia. The latter exhibits discordance of
these features, with low-grade architecture but
high-grade nuclear atypia. Because of the differ-
ences in surgical management of these tumor types,
attention to the nuclear features is of particular
importance in biopsy and frozen section specimens
containing a tumor exhibiting low-grade glandular
architecture.
(2) Secondary features that favor endometrioid carci-
noma are coexistent endometrial hyperplasia,
squamous, mucinous, and/or other forms of
differentiation, polarity of nuclei with a well-
defined luminal border, and microcystic elongated
and fragmented pattern of myoinvasion. Secon-
dary features that favor serous carcinoma are so-
called serous endometrial intraepithelial carcino-
ma, loss of nuclear polarity with detached and
budding tumor cells, serrated or slit-like intra-
luminal gland contours, and so-called “gaping
gland” pattern of myoinvasion. Serous carcinoma
should be considered if the tumor arises in atrophic
endometrium or in an endometrial polyp, although
these features are not specific.
(3) Careful evaluation of tumor morphology reliably
distinguishes most cases of low-grade endometrioid
FIG. 1. In endometrial atypical hyperplasia, the glands are crowded but not confluent (A) and endometrial stroma is preserved around the
glands (B). On occasion, the presence of small foci suggestive of confluent architecture (C, D) within atypical hyperplasia may raise suspicion
for small foci of grade 1 endometrioid carcinoma but may not be interpreted to meet the criteria for a definite diagnosis of malignancy. The
interpretation of such cases can be problematic and subject to interobserver variation, especially since there are no evidence-based guidelines for
the minimum size of confluent growth that predicts myoinvasive endometrioid carcinoma. If the findings are not deemed to meet criteria for
cancer, it is recommended to report the diagnosis as atypical hyperplasia with features suspicious for grade 1 endometrioid carcinoma (or using
equivalent wording).
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FIG. 2. Architectural patterns that meet qualitative criteria for classifying an endometrial proliferation as grade 1 endometrioid carcinoma:
confluent glandular growth (A); cribriform growth (B); confluent papillary growth (C); complex labyrinthine growth (D). There is no
evidence-based consensus on the minimum size of these patterns needed to classify as endometrioid carcinoma. Absence of endometrial stroma
between the glands is required for classification as endometrioid carcinoma (E); however there may be other cell types in between the glands
such as lymphocytes, neutrophils, plasma cells, histiocytes, and/or endothelium of blood vessels (F).
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carcinoma from serous carcinoma. In those cases
where there is morphologic doubt and where further
confirmation is required, the best marker is p53;
aberrant (mutation-type) staining (either the over-
expression pattern or null pattern) favors serous
carcinoma, whereas wild-type staining favors endo-
metrioid carcinoma. p16 is also useful, with diffuse
block-type immunoreactivity favoring serous carci-
noma. The results of these markers should always
be interpreted in conjunction with evaluation of the
tumor morphology, keeping in mind that rare
exceptions exist and that even non-neoplastic
lesions, such as papillary syncytial metaplasia, can
exhibit diffuse p16 staining.
Discussion
Some serous carcinomas may mimic low-grade
endometrioid carcinoma, especially on low-power
magnification (9–12). The distinction between these
2 neoplasms is essential as the surgical and adjuvant
management are vastly different (2).
Two variations of low-grade endometrioid carcino-
ma, 1 of which is architectural and 1 of which is
cytologic, may resemble serous carcinoma. First,
papillary, villoglandular, and small nonvillous papil-
lary architecture may be present, raising concern for
the prototypical papillary architecture of serous
carcinoma (Fig. 3) (9,13). However, cytologic
features of serous carcinoma are not present in these
architectural variants; there is generally no or minimal
nuclear hyperchromasia and an absence of
eosinophilic macronucleoli, significant nuclear
atypia, and atypical mitoses. The presence of
villoglandular and/or papillary patterns in what is
otherwise a typical low-grade endometrioid
carcinoma does not affect the tumor behavior (13).
These patterns, in the absence of severe nuclear
atypia, should be considered as analogs to the
glandular pattern of endometrioid carcinoma when
determining FIGO grade. Thus, it is the concordance
between low-grade architecture and low-grade
cytology that permits distinction of the
villoglandular and papillary variants of low-grade
endometrioid carcinoma from serous carcinoma (11).
Additional features that support classification as
endometrioid carcinoma are squamous, mucinous,
and/or other forms of differentiation (eg, eosinophilic
metaplastic-type differentiation), endometrial
hyperplasia and, in a hysterectomy specimen, the
microcystic elongated and fragmented pattern of
myometrial invasion.
A second setting in which low-grade endometrioid
carcinoma may raise a differential diagnosis with
serous carcinoma is when there is focal or diffuse
moderate nuclear atypia and/or increased mitotic
activity at the higher end of the spectrum of what is
generally observed in endometrioid carcinoma exhib-
iting low-grade architecture. The generally focal
nature of any moderate nuclear atypia and the lack
of diffuse severe atypia favor classification as endo-
metrioid carcinoma, as does the presence of squa-
mous/mucinous differentiation and/or endometrial
hyperplasia. Although mitotic activity is generally
much lower in low-grade endometrioid carcinoma
than in serous carcinoma, there are no studies that
identify a specific mitotic index that reliably distin-
guishes the two tumor types from each other (14).
Conversely, a glandular pattern of serous carcino-
ma may simulate low-grade endometrioid carcinoma
or even atypical endometrial hyperplasia; the latter
may be particularly problematic in endometrial
polyps (Fig. 4) (10,12). At low magnification, the
entire tumor may exhibit simple tubulo-glandular
architecture, without any prototypical architecture of
serous carcinoma such as papillary or solid growth.
However, at high magnification, the tumor cells show
classical cytologic features of severe nuclear atypia,
hyperchromasia, eosinophilic macronucleoli, high
mitotic index, and atypical mitotic figures. Thus, the
discordance between the low-grade architecture and
high-grade cytology usually permits distinction of this
variant of serous carcinoma from low-grade
endometrioid carcinoma (11,12). Secondary features
of serous carcinoma include budding and detachment
of the tumor cells and so-called “gaping gland”
pattern of myoinvasion in hysterectomy specimens.
Serous carcinoma often arises in a background of
atrophic endometrium or in an endometrial polyp;
these features alone are not specific to serous
carcinoma but should raise consideration of this
tumor type. So-called serous endometrial
intraepithelial carcinoma, defined as replacement of
the existing endometrial glands by malignant cells
exhibiting serous morphology and immunophenotype,
is sometimes present adjacent to prototypical serous
carcinoma but is not present in a low-grade
endometrioid carcinoma.
Careful evaluation of tumor morphology is suffi-
cient to distinguish most cases of low-grade endome-
trioid carcinoma from serous carcinoma. In the
occasional setting in which immunohistochemistry is
needed to confirm the morphologic interpretation,
p53 is the best marker (Fig. 5) (12,15–20). Aberrant
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FIG. 3. Low magnification patterns of low-grade endometrioid carcinoma that may be misinterpreted as serous carcinoma include papillary
(A), micropapillary (B), villoglandular (C), and with small non-villous papillae (D, E). Unlike serous carcinoma, the nuclei exhibit minimal
atypia and low mitotic activity (F).
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FIG. 4. The glandular pattern of endometrial serous carcinoma may mimic the architecture of low-grade endometrioid carcinoma at low (A)
and medium (B) magnification. Serous carcinoma may also mimic atypical hyperplasia (C), particularly within an endometrial polyp (D).
However, at high magnification (E, F), serous carcinoma exhibits nuclear pleomorphism, high nuclear to cytoplasmic ratio, macronucleoli, high
mitotic activity, and atypical mitotic figures. None of these features are expected in a low-grade endometrioid carcinoma (Fig. 2E and F).
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(mutation-type) staining is present in virtually all
serous carcinomas, whereas wild-type staining is
present in almost all low-grade endometrioid
carcinomas, although a small proportion of the
latter exhibit mutation-type immunoreactivity. In the
setting of equivocal p53 results, p16 is also useful as it
is diffusely positive in a very high proportion of serous
carcinomas, whereas low-grade endometrioid
carcinomas usually exhibit patchy so-called “mosaic-
type” staining (Fig. 5) (21,22). Even when most of an
endometrioid carcinoma is positive, there are typically
alternating positive and negative foci without diffuse
block-type immunoreactivity. Caution is advised
against interpreting the results of markers in
isolation of the morphologic findings since there are
always occasional exceptions to the typical staining
patterns and even non-neoplastic lesions, such as
papillary syncytial metaplasia of the endometrium,
can be diffusely positive for p16 (23). While other
markers may be of value, there is significant overlap.
In particular, many serous carcinomas are focally or
diffusely positive with estrogen receptor and this
marker is of limited value in distinction from a low-
grade endometrioid carcinoma. Other markers, such
as PTEN, which shows complete loss in a subset of
endometrioid carcinomas but not in serous
carcinoma, may be of some value; however, this
marker is not widely available, can be technically
difficult to perform and there can be problems in
interpretation (12,24).
FIG. 5. Mutation-type p53 immunoexpression in endometrial serous carcinoma is defined as either diffuse strong nuclear staining in > 80% of
tumor cells (A) or complete absence of any staining in tumor cells (B). In the latter setting, weak patchy p53 staining of lymphocytes, stroma
and normal endometrial glands serves as a positive internal control. p53 staining in grade 1 endometrioid carcinoma is weak and patchy (wild-
type immunoreactivity) (C). p16 staining in serous carcinoma is typically diffuse and strong (D) and is typically patchy in grade 1 endometrioid
carcinoma (E).
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DISTINCTION BETWEEN CARCINOSARCOMA
AND ENDOMETRIOID CARCINOMA WITH
CORDED AND HYALINIZED OR SPINDLE
CELL PATTERNS.
Recommendations
(1) The degree of nuclear atypia generally distinguishes
endometrioid carcinoma with corded and hyalinized
pattern or spindle cell features from carcinosarcoma.
The epithelial and mesenchymal components of
carcinosarcoma typically exhibit severe nuclear
atypia, mitotic activity and, often, atypical mitotic
figures. In contrast, these variants of endometrioid
carcinoma typically exhibit low-grade atypia. While
heterologous elements are often present in carcino-
sarcoma, bland-appearing osteoid and chondroid
formation may rarely occur in these low-grade
variants of endometrioid carcinoma.
(2) In carcinosarcoma, the epithelial and mesenchymal
components are usually clearly spatially distinct from
each other without directly blending together. In
contrast, the spindle cell and corded and hyalinized
components typically seamlessly merge with the
conventional glandular component of endometrioid
carcinoma. However, there are exceptions in that
occasionally there is a sharp demarcation between
the spindle cell and corded and hyalinized compo-
nents and the conventional glandular component.
(3) p53 immunohistochemistry may be of value to help
confirm a diagnosis of carcinosarcoma as both the
epithelial and mesenchymal components often exhibit
mutation-type immunoreactivity, in contrast to wild-
type staining in most cases of low-grade endometrioid
carcinoma. Epithelial markers, such as epithelial
membrane antigen (EMA) and broad spectrum
cytokeratins, are often positive at least focally in the
spindle cell and corded components of endometrioid
carcinoma but are generally not expressed (or are
expressed to a limited extent) in the mesenchymal
component of carcinosarcoma.
(4) Grading of corded/hyalinized and spindle cell
variants of endometrioid carcinoma should be
based only on the conventional glandular compo-
nent of endometrioid carcinoma, although it is
acknowledged that evidence-based criteria for
grading in this setting do not exist. Carcinosarco-
ma should be considered a high-grade tumor.
Discussion
Two variants of low-grade endometrioid carcinoma
may morphologically mimic carcinosarcoma. These
are endometrioid carcinoma with spindle cell for-
mation and corded and hyalinized endometrioid
carcinoma; these are likely related neoplasms with
some cases exhibiting overlapping morphologic
features (Fig. 6) (25–27). Outcome data are limited
for these uncommon variants of endometrioid
carcinoma but it appears that the presence of these
variant growth patterns does not alter the behavior
that would be predicted by the grade of the
conventional component of endometrioid carcinoma
and the stage; these are usually, but not always, low-
stage neoplasms (25,26). Although there are no
evidence-based studies regarding grading these
variants of endometrioid carcinoma, the consensus
approach is to base the grade only on evaluation of
the conventional component of endometrioid
carcinoma, which is FIGO grade 1 or 2 in most
cases. For these reasons, these variants should not be
interpreted as carcinosarcoma, which they may
morphologically resemble given their biphasic
appearance. In contrast to these variants,
carcinosarcoma is considered to be a high-grade
endometrial cancer (2,28).
Spindle cell features may be present in endome-
trioid carcinoma of the endometrium or, more
commonly, the ovary (25,26). The tumor cells grow
in vague fascicles, bundles, or nests. They exhibit
spindle cell shape with indistinct cytoplasmic borders.
The areas of spindle cells usually blend seamlessly
with adjacent areas of more conventional endome-
trioid carcinoma which is usually low grade. The
degree of nuclear atypia is usually mild to moderate in
both the spindle cell and conventional glandular areas
of tumor; mitotic activity is also usually relatively low
in the spindled and glandular components. The
spindle cell elements may resemble morules or solid
squamous differentiation, and in some cases there
may be areas of squamous differentiation, including
keratinization. The spindle cells usually exhibit
epithelial differentiation by immunohistochemistry
with positive staining with EMA and broad spectrum
cytokeratins, although the degree of immunoreactivity
is generally less than in the glandular component; p53
exhibits wild-type immunoreactivity.
Spindle cell features may also be observed in corded
and hyalinized endometrioid carcinoma, which is an
endometrioid carcinoma containing cord-like growth
of low-grade epithelioid or spindle cells within a
hyaline or myxoid stroma (25). The cords may
interanastomose or may form small clusters. Discrete
foci of keratinizing squamous differentiation may
occasionally be present within the hyaline or myxoid
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FIG. 6. Corded and hyalinized endometrioid carcinoma (A–D). Spindled and oval tumor cells grow in a streaming (A), corded (B, C) or sex-
cord like pattern within myxoid (C) and/or hyaline (B, D) stroma. Solid growth of spindled cells merge with glandular areas of endometrioid
carcinoma (E). These variants of low-grade endometrioid carcinoma exhibit low-grade nuclear atypia in contrast to carcinosarcoma (F), in
which both the glandular and mesenchymal components exhibit severe nuclear atypia.
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stroma. The corded areas are usually admixed with a
conventional glandular component of endometrioid
carcinoma and the 2 components usually seamlessly
blend together, although occasionally there is a sharp
demarcation. The corded tumor cells exhibit epithelial
differentiation by immunohistochemistry, although
the extent of expression of epithelial markers (EMA
and broad spectrum cytokeratins) is usually less than
in the admixed glandular tumor component. Heterol-
ogous osseous and chondroid differentiation may be
present, although the nuclear features are bland.
Two morphologic features permit distinction of
these variants of endometrioid carcinoma from
carcinosarcoma (29). First, these variant patterns do
not usually exhibit a sharp demarcation from the
areas of conventional endometrioid carcinoma, as is
usual for the mesenchymal and epithelial components
of carcinosarcoma. Instead, the variant patterns and
glandular patterns typically merge seamlessly togeth-
er, although, as discussed, there are occasional
exceptions. Second, the spindle cell and corded
elements do not exhibit severe nuclear atypia, high
mitotic index, or atypical mitoses, which would be
expected in the mesenchymal component of carcino-
sarcoma. When heterologous osseous or chondroid
elements are present in corded and hyalinized
endometrioid carcinoma, the nuclear features are
bland, unlike the usual malignant features of the
heterologous elements in carcinosarcoma. Epithelial
differentiation by immunohistochemistry and wild-
type p53 immunoreactivity are present in spindle cell
or corded and hyalinized variants of endometrioid
carcinoma (25,26). Conversely, the mesenchymal
component of carcinosarcoma exhibits limited or
absent expression of epithelial markers and, along
with the epithelial component, which often exhibits
serous differentiation, commonly shows aberrant
(mutation-type) p53 staining (30–33).
CRITERIA FOR MIXED ENDOMETRIAL CAR-
CINOMA
Recommendations
(1) Mixed endometrial carcinoma is composed of 2 or
more spatially distinct tumor subtypes, at least 1
of which is serous carcinoma or clear cell
carcinoma. The most common combination is an
admixture of endometrioid carcinoma and serous
carcinoma. This term does not apply to morpho-
logic variations of endometrioid carcinoma, se-
rous carcinoma, or clear cell carcinoma, nor does
it apply to endometrioid carcinoma admixed with
mucinous carcinoma, endometrial carcinoma with
ambiguous morphology, dedifferentiated endome-
trial carcinoma or carcinosarcoma.
(2) Any amount of serous carcinoma or clear cell
carcinoma that can be confidently recognized on
routine hematoxylin and eosin–stained sections in
an otherwise endometrioid carcinoma qualifies for
a mixed carcinoma. It is acknowledged that an
evidence-based definition does not exist for the
minimal amount of serous carcinoma or clear cell
carcinoma admixed with endometrioid carcinoma
that carries clinical significance.
(3) Immunohistochemistry to confirm the diagnosis of
each component of tumor is advised, using the
immunostains typically positive (and negative) in
each subtype, as discussed elsewhere in the ISGyP
recommendations.
(4) The pathology report should include a list of each
tumor type (and grade) and their percent compo-
sition. However, the tumor should be graded
overall as high grade (grade 3) regardless of the
relative amount of serous or clear cell carcinoma
present.
Discussion
The definition of mixed endometrial carcinoma has
evolved as the overall classification scheme for endo-
metrial carcinomas has been refined. The 2014 World
Health Organization (WHO) classification defines
mixed endometrial carcinoma as a tumor composed of
2 or more spatially distinct tumor subtypes, at least one
of which is serous carcinoma or clear cell carcinoma
(Fig. 7) (28). The most common mixed endometrial
carcinoma is a mixture of endometrioid carcinoma and
serous carcinoma. Mixed carcinomas with a component
of neuroendocrine carcinoma also occur but these are
not discussed further. The rationale for recognizing
mixed endometrial carcinoma is that even a minor
component of serous or clear cell carcinoma within an
otherwise typical endometrioid carcinoma may confer
an adverse outcome similar to a pure serous or clear
cell carcinoma. Importantly, this entity is a diagnosis
of exclusion. First, the term should not be used
for pathologically distinct tumor types, such as
dedifferentiated endometrial carcinoma or
carcinosarcoma (29,34,35). Second, the term should
not be used for morphologic variants of endometrioid
carcinoma that simulate serous carcinoma (eg,
villoglandular or papillary variants of endometrioid
carcinoma) or clear cell carcinoma (eg, clear cell change
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FIG. 7. Biopsies of mixed endometrial carcinomas. Each contains a spatially distinct component of low-grade endometrioid carcinoma but the
high grade component defines the behavior and management. Mixed serous carcinoma and endometrioid carcinoma (A–C). B is a high-
magnification view of the serous component and C of the endometrioid component. Mixed clear cell carcinoma and endometrioid carcinoma
(D, E). Mixed high grade neuroendocrine carcinoma and endometrioid carcinoma (F–H); G is a high-magnification view of the neuroendocrine
component and H of the endometrioid component.
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in endometrioid carcinoma) (9). Finally, the term should
not be used for cases with ambiguous morphology that
defy classification (36). Thus, as a diagnosis after
exclusion of a number of other tumors, true cases of
mixed endometrial carcinoma are exceedingly rare. Not
surprisingly, mixed endometrial carcinoma remains a
common source of interobserver disagreement in
endometrial cancer subtyping (37–41).
Two modifications to the WHO criteria for mixed
endometrial carcinoma are advised. First, immuno-
histochemistry is recommended to help confirm the
subtype of each component, using the suggested
markers (positive and negative) for each individual
subtype. This strategy mitigates against misinter-
preting morphologic variations of endometrioid car-
cinoma, such as those with villoglandular, papillary,
or clear cell features, as a separate component of
serous or clear cell carcinoma. Second, it is advised
that any amount of serous carcinoma or clear cell
carcinoma that can be confidently recognized to
coexist with endometrioid carcinoma qualifies as a
mixed epithelial carcinoma. This strategy differs
slightly from the WHO criterion which recommends
that the serous or clear cell carcinoma component
must comprise at least 5% of the overall tumor. The
WHO recommendation was based on studies that
used a 5% threshold for the minor component;
however, there are no outcome studies that have
addressed tumors that fall under that threshold. Until
such studies are available, it is recommended not to
use a specific quantitative threshold to exclude cases
that clearly exhibit prototypical features of serous
carcinoma or clear cell carcinoma.
The pathogenesis of mixed endometrial carcinoma
remains to be fully elucidated. Recent molecular
genetic studies suggest that some may represent
collision tumors composed of genetically independent
tumors while others may represent progression or
divergence from a common origin with the serous or
clear cell component deriving from the endometrioid
carcinoma (42,43).
Two other endometrial carcinomas that contain
spatially distinct components of tumor types are
dedifferentiated endometrial carcinoma and carcino-
sarcoma. However, these are both pathologically
distinct tumors that should not be classified as mixed
endometrial carcinoma but as their own subtypes.
Dedifferentiated endometrial carcinoma consists of
an undifferentiated component (i.e. undifferentiated
endometrial carcinoma) and a spatially distinct low-
grade endometrioid component (28,34,35). Dediffer-
entiated endometrial carcinoma exhibits aggressive
behavior even when the amount of undifferentiated
endometrial carcinoma is minor (34,35,44,45). Mis-
match repair gene defects and mutations of the switch/
sucrose non-fermentable chromatin remodeling com-
plex are common (46–49). Undifferentiated endome-
trial carcinoma typically appears as sheets of
noncohesive monomorphic tumor cells that are
negative or only focally positive for epithelial markers
(broad spectrum cytokeratins, EMA), Mullerian
markers (PAX8, estrogen receptor), and cell adhesion
(E-cadherin) markers. Some undifferentiated endome-
trial carcinomas may also exhibit rhabdoid features,
cord-like growth, or a myxoid stroma. Switch/sucrose
non-fermentable complex component (SMARCA2,
SMARCA4, SMARCB1, ARID1A, and/or
ARID1B) deficiency and loss of mismatch repair
protein expression are common immunohistochemical
features of undifferentiated endometrial carcinoma
and the dedifferentiated component of dedifferenti-
ated endometrial carcinoma (46–49).
Carcinosarcoma contains a malignant epithelial
component that may reflect various histologic types
(eg, serous, endometrioid, clear cell) and a spatially
distinct malignant mesenchymal component that may
include heterologous differentiation (29). Carcinosar-
coma is a distinct tumor type and should not be
classified as mixed endometrial carcinoma.
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